A novel therapeutic approach utilizing broadly neutralizing antibodies (bnAbs) has demonstrated sustained viral suppression in a cohort of participants with HIV, according to research published today in The Latest England Journal of Medicine. The study, appearing in the February 12, 2026, issue (Volume 394, Issue 7, pages 716-721), details the outcomes of a Phase 1/2 clinical trial evaluating the efficacy and safety of the bnAb combination.
The trial focused on individuals who had been on stable antiretroviral therapy (ART) for at least six months, achieving viral suppression. Participants were randomized to receive either the bnAb combination administered intravenously every two weeks, or continue with their existing ART regimen. The primary endpoint of the study was the proportion of participants maintaining viral suppression after discontinuing ART, while receiving the bnAb therapy.
Researchers reported that a significant percentage of participants in the bnAb arm were able to maintain viral control for an extended period following ART cessation. While specific numbers were detailed in the journal publication, the findings suggest a potential pathway towards ART-free remission for individuals living with HIV. The mechanism of action involves the bnAbs’ ability to neutralize a wide range of HIV strains, preventing viral replication.
The study also assessed the safety profile of the bnAb combination. Adverse events were generally mild to moderate in severity and primarily consisted of infusion-related reactions. No serious safety concerns were identified during the trial period. Further investigation into long-term safety and durability of response is ongoing.
The New England Journal of Medicine has previously published research related to HIV treatment and prevention, including articles from June 26, 2025, and April 3, 2025, highlighting ongoing efforts to combat the global HIV epidemic. The NEJM Blog, “HIV and ID Observations,” also provides regular updates on advancements in HIV research and clinical care.
Researchers are now planning larger, Phase 3 clinical trials to confirm these findings and evaluate the bnAb combination in a more diverse population of individuals with HIV. The ultimate goal is to develop a curative strategy that eliminates the need for lifelong ART, improving the quality of life for millions living with the virus. The study’s authors have indicated that further research will focus on optimizing the dosing regimen and identifying biomarkers predictive of response to bnAb therapy.
